Literature DB >> 19427916

AMP-activated protein kinase and carbohydrate response element binding protein: a study of two potential regulatory factors in the hepatic lipogenic program of broiler chickens.

Monika Proszkowiec-Weglarz1, Mark P Richards, Brooke D Humphrey, Robert W Rosebrough, John P McMurtry.   

Abstract

This study investigated the effects of fasting and refeeding on AMP-activated protein kinase (AMPK) and carbohydrate response element binding protein (ChREBP) mRNA, protein and activity levels; as well as the expression of lipogenic genes involved in regulating lipid synthesis in broiler chicken (Gallus gallus) liver. Fasting for 24 or 48 h produced significant declines in plasma glucose (at 24 h), insulin and thyroid hormone (T3) levels that were accompanied by changes in mRNA expression levels of hepatic lipogenic genes. The mRNA levels of malic enzyme (ME), ATP-citrate lyase (ACL), acetyl-CoA carboxylase alpha (ACCalpha), fatty acid synthase (FAS), stearoyl-CoA desaturase-1 (SCD-1) and thyroid hormone responsive Spot 14 (Spot 14) declined in response to fasting. Refeeding for 24 h increased mRNA levels for each of these genes, characterized by a significant increase ('overshoot') above fed control values. No change in mRNA expression of the two AMPK alpha subunit genes was observed in response to fasting or refeeding. In contrast, ChREBP and sterol regulatory element binding protein-1 (SREBP-1) mRNA levels decreased during fasting and increased with refeeding. Phosphorylation of AMPK alpha subunits increased modestly after a 48 h fast. However, there was no corresponding change in the phosphorylation of ACC, a major downstream target of AMPK. Protein level and DNA-binding activity of ChREBP increased during fasting and declined upon refeeding as measured in whole liver tissue extracts. In general, evidence was found for coordinate transcriptional regulation of lipogenic program genes in broiler chicken liver, but specific regulatory roles for AMPK and ChREBP in that process remain to be further characterized.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19427916     DOI: 10.1016/j.cbpb.2009.05.003

Source DB:  PubMed          Journal:  Comp Biochem Physiol B Biochem Mol Biol        ISSN: 1096-4959            Impact factor:   2.231


  6 in total

Review 1.  Have guidelines addressing physical activity been established in nonalcoholic fatty liver disease?

Authors:  Carmine Finelli; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2012-12-14       Impact factor: 5.742

2.  Delayed access to feed alters expression of genes associated with carbohydrate and amino acid utilization in newly hatched broiler chicks.

Authors:  Jason A Payne; Monika Proszkowiec-Weglarz; Laura E Ellestad
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-10-09       Impact factor: 3.619

3.  Effect of a straw-derived xylooligosaccharide on broiler growth performance, endocrine metabolism, and immune response.

Authors:  Sun Zhenping; Lv Wenting; Yu Ruikui; Li Jia; Liu Honghong; Sun Wei; Wang Zhongmie; Li Jingpan; Shan Zhe; Qin Yuling
Journal:  Can J Vet Res       Date:  2013-04       Impact factor: 1.310

4.  Effect of 24 h Fasting on Gene Expression of AMPK, Appetite Regulation Peptides and Lipometabolism Related Factors in the Hypothalamus of Broiler Chicks.

Authors:  Liu Lei; Zhu Lixian
Journal:  Asian-Australas J Anim Sci       Date:  2012-09       Impact factor: 2.509

5.  Effects of a bioactive olive pomace extract from Olea europaea on growth performance, gut function, and intestinal microbiota in broiler chickens.

Authors:  J Herrero-Encinas; M Blanch; J J Pastor; A Mereu; I R Ipharraguerre; D Menoyo
Journal:  Poult Sci       Date:  2019-12-30       Impact factor: 3.352

6.  Diet Supplementation with a Bioactive Pomace Extract from Olea europaea Partially Mitigates Negative Effects on Gut Health Arising from a Short-Term Fasting Period in Broiler Chickens.

Authors:  Javier Herrero-Encinas; Marta Blanch; José J Pastor; David Menoyo
Journal:  Animals (Basel)       Date:  2020-02-22       Impact factor: 3.231

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.